Overactive Bladder Treatment Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Overactive Bladder Treatment Market to 2027 - Global Analysis and Forecasts by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation and Intravesical Instillation); Disease (Idiopathic Overactive Bladder and Neurogenic Overactive Bladder)

Report Code: TIPRE00004082 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Overactive Bladder is a general medical condition where there are sudden pressures of urination coupled with urine leakage condition known as incontinence. The frequency of urination in patients is around eight times a day.

MARKET DYNAMICS
The Overactive Bladder Treatment Market is anticipated to grow in the forecast period owing to driving factors such as increasing awareness about the importance of diagnosis and treatment of the disease, increasing number of drug development programs and increasing expenditure for R&D. nevertheless, patent expiry of some of the key drugs and unfavorable side effects is expected to restrict the market growth during the forecast period.

MARKET SCOPE
The "Global Overactive Bladder Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Overactive Bladder Treatment Market with detailed market segmentation by Pharmacotherapy, Disease and Geography. The global Overactive Bladder Treatment Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Overactive Bladder Treatment Market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global is segmented on the basis of Pharmacotherapy and Disease. Based on Pharmacotherapy the market is segmented into Anticholinergics, Mirabegron, Botox, Neurostimulation and Intravesical Instillation. Anticholinergics is further segmented into Solifenacin, Oxybutynin, Fesoterodine, Darifenacin, Tolterodine, Trospium and Other Anticholinergics. Based on Disease the market is segmented into Idiopathic Overactive Bladder and Neurogenic Overactive Bladder.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Overactive Bladder Treatment Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Overactive Bladder Treatment Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Overactive Bladder Treatment Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Overactive Bladder Treatment Market in these regions.

MARKET PLAYERS
The reports cover key developments in the Overactive Bladder Treatment Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Overactive Bladder Treatment Market are anticipated to lucrative growth opportunities in the future with the rising demand for Overactive Bladder Treatment Market in the global market. Below mentioned is the list of few companies engaged in the Overactive Bladder Treatment Market.

The report also includes the profiles of key Overactive Bladder Treatment Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Limited
  • Allergan, PLC.
  • Mylan N.V.
  • Endo International PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi
  • Aurobindo Pharma Limited
  • Intas Pharmaceuticals Ltd.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Overactive Bladder Treatment Market - By Pharmacotherapy
1.3.2 Overactive Bladder Treatment Market - By Disease
1.3.3 Overactive Bladder Treatment Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. OVERACTIVE BLADDER TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. OVERACTIVE BLADDER TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. OVERACTIVE BLADDER TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. OVERACTIVE BLADDER TREATMENT - GLOBAL MARKET OVERVIEW
6.2. OVERACTIVE BLADDER TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. OVERACTIVE BLADDER TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - PHARMACOTHERAPY
7.1. OVERVIEW
7.2. PHARMACOTHERAPY MARKET FORECASTS AND ANALYSIS
7.3. ANTICHOLINERGICS
7.3.1. Overview
7.3.2. Anticholinergics Market Forecast and Analysis
7.3.3. Solifenacin Market
7.3.3.1. Overview
7.3.3.2. Solifenacin Market Forecast and Analysis
7.3.4. Oxybutynin Market
7.3.4.1. Overview
7.3.4.2. Oxybutynin Market Forecast and Analysis
7.3.5. Fesoterodine Market
7.3.5.1. Overview
7.3.5.2. Fesoterodine Market Forecast and Analysis
7.3.6. Darifenacin Market
7.3.6.1. Overview
7.3.6.2. Darifenacin Market Forecast and Analysis
7.3.7. Tolterodine Market
7.3.7.1. Overview
7.3.7.2. Tolterodine Market Forecast and Analysis
7.3.8. Trospium and Other Anticholinergics Market
7.3.8.1. Overview
7.3.8.2. Trospium and Other Anticholinergics Market Forecast and Analysis
7.4. MIRABEGRON, BOTOX, NEUROSTIMULATION AND INTRAVESICAL INSTILLATION
7.4.1. Overview
7.4.2. Mirabegron, Botox, Neurostimulation and Intravesical Instillation Market Forecast and Analysis
8. OVERACTIVE BLADDER TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE
8.1. OVERVIEW
8.2. DISEASE MARKET FORECASTS AND ANALYSIS
8.3. IDIOPATHIC OVERACTIVE BLADDER AND NEUROGENIC OVERACTIVE BLADDER
8.3.1. Overview
8.3.2. Idiopathic Overactive Bladder and Neurogenic Overactive Bladder Market Forecast and Analysis
9. OVERACTIVE BLADDER TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Overactive Bladder Treatment Market Overview
9.1.2 North America Overactive Bladder Treatment Market Forecasts and Analysis
9.1.3 North America Overactive Bladder Treatment Market Forecasts and Analysis - By Pharmacotherapy
9.1.4 North America Overactive Bladder Treatment Market Forecasts and Analysis - By Disease
9.1.5 North America Overactive Bladder Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Overactive Bladder Treatment Market
9.1.5.1.1 United States Overactive Bladder Treatment Market by Pharmacotherapy
9.1.5.1.2 United States Overactive Bladder Treatment Market by Disease
9.1.5.2 Canada Overactive Bladder Treatment Market
9.1.5.2.1 Canada Overactive Bladder Treatment Market by Pharmacotherapy
9.1.5.2.2 Canada Overactive Bladder Treatment Market by Disease
9.1.5.3 Mexico Overactive Bladder Treatment Market
9.1.5.3.1 Mexico Overactive Bladder Treatment Market by Pharmacotherapy
9.1.5.3.2 Mexico Overactive Bladder Treatment Market by Disease
9.1.5.4 US Overactive Bladder Treatment Market
9.1.5.4.1 US Overactive Bladder Treatment Market by Pharmacotherapy
9.1.5.4.2 US Overactive Bladder Treatment Market by Disease
9.2. EUROPE
9.2.1 Europe Overactive Bladder Treatment Market Overview
9.2.2 Europe Overactive Bladder Treatment Market Forecasts and Analysis
9.2.3 Europe Overactive Bladder Treatment Market Forecasts and Analysis - By Pharmacotherapy
9.2.4 Europe Overactive Bladder Treatment Market Forecasts and Analysis - By Disease
9.2.5 Europe Overactive Bladder Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Overactive Bladder Treatment Market
9.2.5.1.1 Germany Overactive Bladder Treatment Market by Pharmacotherapy
9.2.5.1.2 Germany Overactive Bladder Treatment Market by Disease
9.2.5.2 France Overactive Bladder Treatment Market
9.2.5.2.1 France Overactive Bladder Treatment Market by Pharmacotherapy
9.2.5.2.2 France Overactive Bladder Treatment Market by Disease
9.2.5.3 Italy Overactive Bladder Treatment Market
9.2.5.3.1 Italy Overactive Bladder Treatment Market by Pharmacotherapy
9.2.5.3.2 Italy Overactive Bladder Treatment Market by Disease
9.2.5.4 Spain Overactive Bladder Treatment Market
9.2.5.4.1 Spain Overactive Bladder Treatment Market by Pharmacotherapy
9.2.5.4.2 Spain Overactive Bladder Treatment Market by Disease
9.2.5.5 United Kingdom Overactive Bladder Treatment Market
9.2.5.5.1 United Kingdom Overactive Bladder Treatment Market by Pharmacotherapy
9.2.5.5.2 United Kingdom Overactive Bladder Treatment Market by Disease
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Overactive Bladder Treatment Market Overview
9.3.2 Asia-Pacific Overactive Bladder Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Overactive Bladder Treatment Market Forecasts and Analysis - By Pharmacotherapy
9.3.4 Asia-Pacific Overactive Bladder Treatment Market Forecasts and Analysis - By Disease
9.3.5 Asia-Pacific Overactive Bladder Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Overactive Bladder Treatment Market
9.3.5.1.1 Australia Overactive Bladder Treatment Market by Pharmacotherapy
9.3.5.1.2 Australia Overactive Bladder Treatment Market by Disease
9.3.5.2 China Overactive Bladder Treatment Market
9.3.5.2.1 China Overactive Bladder Treatment Market by Pharmacotherapy
9.3.5.2.2 China Overactive Bladder Treatment Market by Disease
9.3.5.3 India Overactive Bladder Treatment Market
9.3.5.3.1 India Overactive Bladder Treatment Market by Pharmacotherapy
9.3.5.3.2 India Overactive Bladder Treatment Market by Disease
9.3.5.4 Japan Overactive Bladder Treatment Market
9.3.5.4.1 Japan Overactive Bladder Treatment Market by Pharmacotherapy
9.3.5.4.2 Japan Overactive Bladder Treatment Market by Disease
9.3.5.5 South Korea Overactive Bladder Treatment Market
9.3.5.5.1 South Korea Overactive Bladder Treatment Market by Pharmacotherapy
9.3.5.5.2 South Korea Overactive Bladder Treatment Market by Disease
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Overactive Bladder Treatment Market Overview
9.4.2 Middle East and Africa Overactive Bladder Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Overactive Bladder Treatment Market Forecasts and Analysis - By Pharmacotherapy
9.4.4 Middle East and Africa Overactive Bladder Treatment Market Forecasts and Analysis - By Disease
9.4.5 Middle East and Africa Overactive Bladder Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Overactive Bladder Treatment Market
9.4.5.1.1 South Africa Overactive Bladder Treatment Market by Pharmacotherapy
9.4.5.1.2 South Africa Overactive Bladder Treatment Market by Disease
9.4.5.2 Saudi Arabia Overactive Bladder Treatment Market
9.4.5.2.1 Saudi Arabia Overactive Bladder Treatment Market by Pharmacotherapy
9.4.5.2.2 Saudi Arabia Overactive Bladder Treatment Market by Disease
9.4.5.3 U.A.E Overactive Bladder Treatment Market
9.4.5.3.1 U.A.E Overactive Bladder Treatment Market by Pharmacotherapy
9.4.5.3.2 U.A.E Overactive Bladder Treatment Market by Disease
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Overactive Bladder Treatment Market Overview
9.5.2 South and Central America Overactive Bladder Treatment Market Forecasts and Analysis
9.5.3 South and Central America Overactive Bladder Treatment Market Forecasts and Analysis - By Pharmacotherapy
9.5.4 South and Central America Overactive Bladder Treatment Market Forecasts and Analysis - By Disease
9.5.5 South and Central America Overactive Bladder Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Overactive Bladder Treatment Market
9.5.5.1.1 Brazil Overactive Bladder Treatment Market by Pharmacotherapy
9.5.5.1.2 Brazil Overactive Bladder Treatment Market by Disease
9.5.5.2 Argentina Overactive Bladder Treatment Market
9.5.5.2.1 Argentina Overactive Bladder Treatment Market by Pharmacotherapy
9.5.5.2.2 Argentina Overactive Bladder Treatment Market by Disease
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. OVERACTIVE BLADDER TREATMENT MARKET, KEY COMPANY PROFILES
11.1. ASTELLAS PHARMA INC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. PFIZER, INC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. TEVA PHARMACEUTICAL
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ALLERGAN, PLC
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MYLAN N.V
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ENDO INTERNATIONAL PLC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. HISAMITSU PHARMACEUTICAL CO., INC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. SANOFI
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. AUROBINDO PHARMA LIMITED
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. INTAS PHARMACEUTICALS LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

- Astellas Pharma Inc.
- Pfizer, Inc.
- Teva Pharmaceutical Industries Limited
- Allergan, PLC.
- Mylan N.V.
- Endo International PLC
- Hisamitsu Pharmaceutical Co., Inc.
- Sanofi
- Aurobindo Pharma Limited
- Intas Pharmaceuticals Ltd.